Subtype-selective KCa2.2 activators that avoid potential side effects associated with activation of peripheral KCa3.1 channels are critically needed to target KCa2.2 channels in the central nervous system for the treatment of spinocerebellar ataxia and essential tremor. The gene discussed is KCNN2; the disease is essential tremor.